View all the latest information in myeloproliferative neoplasms, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.
5-year results from the PROUD-PV and CONTINUATION-PV studies
Ropeginterferon alfa-2b is a novel pegylated recombinant interferon, approved in the EU as monotherapy for the treatment of adults with...
Interferon therapy in the management of myeloproliferative neoplasms
Treatment with interferon (IFN) therapy is considered successful for patients with myeloproliferative neoplasms (MPN), such as...
Clinical factors associated with response to ruxolitinib in patients with myelofibrosis
A dysregulated Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is...
Withdrawal of ruxolitinib increases risk of mortality in patients with myelofibrosis and COVID-19
Outcomes of coronavirus 2019 disease (COVID-19) in patients with MPN are still not fully understood...
How should conditioning be performed before transplanting a patient with MF?
During the 2021 TCT Meetings Digital Experience, the MPN Hub spoke to Craig W. Freyer, University of Pennsylvania,...
Genetic factors are more important than disease activity for transplantation outcomes in patients with MPN-BP
Myeloproliferative neoplasms (MPN) in the blast phase (BP) are defined as ≥ 20%...
Results from an ongoing phase II study of IMG-7289 (bomedemstat) in patients with advanced MF
Many patients with myelofibrosis (MF) become intolerant or resistant to currently approved JAK inhibitors,...
IMG-7289 (bomedemstat) has been granted access to the European Medicines Agency PRIME scheme for the treatment of myelofibrosis
IMG-7289 (bomedemstat), a lysine-specific demethylase-1 (LSD-1)...
Non-steroidal anti-inflammatory drugs
PI3 kinase inhibitors